vs

Side-by-side financial comparison of Essent Group Ltd. (ESNT) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $312.4M, roughly 1.0× Essent Group Ltd.). Essent Group Ltd. runs the higher net margin — 49.6% vs -18.2%, a 67.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs -0.8%). Essent Group Ltd. produced more free cash flow last quarter ($848.7M vs $-133.8M).

Essentra PLC is a supplier of plastic and fibre products. The company operates internationally from headquarters in Kidlington, Oxfordshire. It is listed on the London Stock Exchange.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

ESNT vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.0× larger
MDGL
$321.1M
$312.4M
ESNT
Growing faster (revenue YoY)
MDGL
MDGL
+211.6% gap
MDGL
210.8%
-0.8%
ESNT
Higher net margin
ESNT
ESNT
67.9% more per $
ESNT
49.6%
-18.2%
MDGL
More free cash flow
ESNT
ESNT
$982.5M more FCF
ESNT
$848.7M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESNT
ESNT
MDGL
MDGL
Revenue
$312.4M
$321.1M
Net Profit
$155.0M
$-58.6M
Gross Margin
Operating Margin
59.1%
-18.6%
Net Margin
49.6%
-18.2%
Revenue YoY
-0.8%
210.8%
Net Profit YoY
-7.7%
1.4%
EPS (diluted)
$1.61
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESNT
ESNT
MDGL
MDGL
Q4 25
$312.4M
$321.1M
Q3 25
$311.8M
$287.3M
Q2 25
$319.1M
$212.8M
Q1 25
$317.6M
$137.3M
Q4 24
$315.0M
$103.3M
Q3 24
$316.6M
$62.2M
Q2 24
$312.9M
Q1 24
$298.4M
$0
Net Profit
ESNT
ESNT
MDGL
MDGL
Q4 25
$155.0M
$-58.6M
Q3 25
$164.2M
$-114.2M
Q2 25
$195.3M
$-42.3M
Q1 25
$175.4M
$-73.2M
Q4 24
$167.9M
$-59.4M
Q3 24
$176.2M
$-107.0M
Q2 24
$203.6M
Q1 24
$181.7M
$-147.5M
Gross Margin
ESNT
ESNT
MDGL
MDGL
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ESNT
ESNT
MDGL
MDGL
Q4 25
59.1%
-18.6%
Q3 25
63.9%
-39.7%
Q2 25
72.4%
-22.2%
Q1 25
65.2%
-57.8%
Q4 24
61.9%
-64.8%
Q3 24
65.6%
-187.1%
Q2 24
76.4%
Q1 24
71.6%
Net Margin
ESNT
ESNT
MDGL
MDGL
Q4 25
49.6%
-18.2%
Q3 25
52.7%
-39.8%
Q2 25
61.2%
-19.9%
Q1 25
55.2%
-53.4%
Q4 24
53.3%
-57.5%
Q3 24
55.6%
-172.0%
Q2 24
65.1%
Q1 24
60.9%
EPS (diluted)
ESNT
ESNT
MDGL
MDGL
Q4 25
$1.61
$-2.55
Q3 25
$1.67
$-5.08
Q2 25
$1.93
$-1.90
Q1 25
$1.69
$-3.32
Q4 24
$1.59
$-2.50
Q3 24
$1.65
$-4.92
Q2 24
$1.91
Q1 24
$1.70
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESNT
ESNT
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$5.8B
$602.7M
Total Assets
$7.4B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESNT
ESNT
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q2 24
Q1 24
$622.5M
Total Debt
ESNT
ESNT
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
ESNT
ESNT
MDGL
MDGL
Q4 25
$5.8B
$602.7M
Q3 25
$5.7B
$625.7M
Q2 25
$5.7B
$696.0M
Q1 25
$5.7B
$710.6M
Q4 24
$5.6B
$754.4M
Q3 24
$5.6B
$777.2M
Q2 24
$5.4B
Q1 24
$5.2B
$850.8M
Total Assets
ESNT
ESNT
MDGL
MDGL
Q4 25
$7.4B
$1.3B
Q3 25
$7.4B
$1.4B
Q2 25
$7.2B
$1.0B
Q1 25
$7.2B
$996.6M
Q4 24
$7.1B
$1.0B
Q3 24
$7.1B
$1.1B
Q2 24
$6.7B
Q1 24
$6.6B
$1.1B
Debt / Equity
ESNT
ESNT
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESNT
ESNT
MDGL
MDGL
Operating Cash FlowLast quarter
$856.1M
$-133.5M
Free Cash FlowOCF − Capex
$848.7M
$-133.8M
FCF MarginFCF / Revenue
271.7%
-41.7%
Capex IntensityCapex / Revenue
2.4%
0.1%
Cash ConversionOCF / Net Profit
5.52×
TTM Free Cash FlowTrailing 4 quarters
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESNT
ESNT
MDGL
MDGL
Q4 25
$856.1M
$-133.5M
Q3 25
$215.9M
$79.8M
Q2 25
$189.5M
$-47.1M
Q1 25
$221.6M
$-88.9M
Q4 24
$861.5M
$-104.5M
Q3 24
$229.2M
$-67.0M
Q2 24
$188.7M
Q1 24
$216.9M
$-149.2M
Free Cash Flow
ESNT
ESNT
MDGL
MDGL
Q4 25
$848.7M
$-133.8M
Q3 25
$210.6M
$79.0M
Q2 25
$188.8M
Q1 25
$221.3M
Q4 24
$854.8M
$-104.7M
Q3 24
$228.7M
$-67.8M
Q2 24
$187.6M
Q1 24
$212.5M
$-149.5M
FCF Margin
ESNT
ESNT
MDGL
MDGL
Q4 25
271.7%
-41.7%
Q3 25
67.5%
27.5%
Q2 25
59.2%
Q1 25
69.7%
Q4 24
271.3%
-101.3%
Q3 24
72.2%
-109.0%
Q2 24
60.0%
Q1 24
71.2%
Capex Intensity
ESNT
ESNT
MDGL
MDGL
Q4 25
2.4%
0.1%
Q3 25
1.7%
0.3%
Q2 25
0.2%
0.0%
Q1 25
0.1%
0.0%
Q4 24
2.1%
0.2%
Q3 24
0.2%
1.3%
Q2 24
0.3%
Q1 24
1.5%
Cash Conversion
ESNT
ESNT
MDGL
MDGL
Q4 25
5.52×
Q3 25
1.31×
Q2 25
0.97×
Q1 25
1.26×
Q4 24
5.13×
Q3 24
1.30×
Q2 24
0.93×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESNT
ESNT

Mortgage Insurance Segment$192.4M62%
Other$120.0M38%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons